SEC EDGARSep 16$BNTX

Sahin Ugur sold $4.7M of BNTX

Sahin Ugur (Chief Executive Officer) sold 49,000 shares of BioNTech SE (BNTX) at an average of $96.37 ($96.09–$96.49, $4.72M total) across 2 trades over 2026-09-15 to 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Sahin Ugur

Published Sep 16, 2026, 8:46 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 16, 2026, 8:50 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$BNTX

Bearish

medium confidence

Mentioned

$BNTX

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$BNTXBearishLow

Why it matters

The CEO's sale reduces his ownership percentage, which may be interpreted by the market as reduced confidence, potentially prompting short‑term price weakness.

Market read

Insider sell by the CEO is a notable event for traders monitoring BioNTech's stock, offering a potential short‑term trade signal.

What to watch

Potential upcoming clinical data releases or financing needs that prompted the sale.

Relevance 5/10Novelty 7/10Timing: filing today

Background

Form 4 filings are primary disclosures of insider transactions, providing fresh data on insider holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BNTXBearishMedium confidence

Context

CEO Sahin Ugur sold 49,000 shares for $4.7M via a 10b5-1 plan, reducing his stake to 553,209 shares.

Expected impact

Possible modest downside pressure in the next few trading sessions.

Evidence & confidence

Insider sales by a CEO are closely watched; the $4.7M sale is material for BioNTech and could trigger sell‑offs.

Market effects

Sector

May raise questions about biotech sector confidence in BioNTech's pipeline.

Regional

Limited to US and European biotech investors.

Global

Low global impact; primarily relevant to BioNTech shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing under a pre‑arranged 10b5‑1 plan, not a negative signal.

Key entities

Officer
Sahin Ugur
Chief Executive Officer of BioNTech
Company
BioNTech SE
German biotech firm developing mRNA therapies

Read at source ← All news

$BNTXHighAI 8/10

BioNTech to buy Scholar Rock PRV for $205M (BNTX:NASDAQ)

BioNTech (BNTX) agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock (SRRK) for $205M to expedite its oncology pipeline. The deal aims to reduce FDA review times.

seekingalpha.comNov 10

$BNTXMed

BioNTech Agrees to Acquire FDA Priority Review Voucher for $205 Million

BioNTech (BNTX) agreed to buy a U.S. FDA Priority Review Voucher from Scholar Rock for $205M, aiming to expedite future drug approvals. The deal is subject to regulatory approval. Analysts have mixed views on BNTX stock, with a Buy rating and $110 target, but Spark's AI rates it Neutral due to earnings and cash flow concerns.

tipranks.comNov 10

$SRRKMedAI 8/10

Scholar Rock to Sell FDA Priority Review Voucher to BioNTech for $205 Million

Scholar Rock (SRRK) agreed to sell its FDA Priority Review Voucher to BioNTech for $205M in cash. The payment is due at closing, pending regulatory approval. The voucher was awarded after FDA approval of ISEMBYLD. The transaction aims to monetize the voucher.

tradingview.comNov 10

$BNTXMed

BNTX: BioNTech agrees to buy FDA priority review voucher for $205M

BioNTech (BNTX) agreed to buy an FDA Priority Review Voucher from Scholar Rock (SRRK) for $205M in cash, pending HSR clearance. The voucher will expedite a future oncology filing in its late-stage pipeline.

quantisnow.comNov 10

$MRNAHighAI 8/10

Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher

Moderna (MRNA) shares rose 5% after reporting a surprise Q3 2026 profit of $0.38 EPS, beating forecasts. Revenue increased 29% YoY to $1.31B, driven by international COVID-19 vaccine sales. The company raised its 2026 revenue growth outlook to 15-25%. Pfizer (PFE) and BioNTech (BNTX) showed minimal movement.

247wallst.comNov 6

$BNTXMedAI 8/10

BioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliver

BioNTech raised its 2026 revenue guidance to €1.7B-€1.9B, driven by non-COVID-19 development activities. Q3 revenue was €1.289B, with net profit of €184.5M. BMS collaboration contributed €613M in Q3, surpassing COVID-19 vaccine revenue. The company has €16.2B in cash and is investing heavily in oncology pipeline, including pumitamig and gotistobart.

european-biotechnology.comNov 5